

[View this email in your browser](#)



REPRIEVE

Randomized Trial to Prevent Vascular Events in HIV

[A review of shipping specimens to the repository will take place during the Monthly Site Call on Tuesday, September 17th.](#) Make every effort to ensure that the person responsible for shipping specimens to the repository at your site joins this call.



Share REPRIEVE trial updates with fellow clinicians and study teams!

During this phase of the trial, it is important to continue generating excitement about REPRIEVE and remind your participants and staff of the importance of the study. To help you with this we have updated the provider slide deck* that you may adapt for presentations to study teams, staff, and interested colleagues. Download the updated slide deck by [clicking here!](#)

**Please note that the data in the slides are provided for presentation purposes only and cannot be submitted for abstract or publication purposes.*

ATTN: Sites in Hurricane Regions




Please be aware that we are currently in the peak of hurricane season (late August – September). If your site is in a region that may be affected by hurricanes, please be cautious when sending specimens to BRI. If you need to send specimens to BRI out of your assigned schedule, make arrangements with the repository manager by emailing: brirepository@afbr-bri.com.

And most importantly... STAY SAFE!

Have you heard about the *REPRIEVE Ambassador Project*?

As part of our ongoing retention efforts, the REPRIEVE CCC is making an effort to visit all REPRIEVE sites! Over the course of the next few months, Katie and Emma from the REPRIEVE CCC may be reaching out to schedule a visit at your site. These are *friendly, informal* meetings where CCC team members will discuss the status of the trial, review the recent protocol amendment, retention methods, and any other topics or questions your team would like to address. Sites have found these visits very useful and enjoyable so far! If you would like to schedule a visit email ekileel@mgh.harvard.edu





Before you ship, do a 100% QA/QC of your storage box!

- Check the Global Specimen ID. The global ID is specific to each aliquot and ends with -001, -002, etc...
- Check the vial location. Each vial location in the physical box should PERFECTLY match your Shipping Manifest and Shipping Container Report (box map). Ensure that there are no missing vials or extra vials.
- Check that each label is clearly printed and legible.

Please read section 14.4 of the REPRIEVE (A5332) MOPS located on the PSWP about shipment evaluations. If a response to a shipment evaluation is requested, please do so within 1 week of receiving the shipment evaluation to avoid penalty.

NEW *My Heart Matters Blog* by Follow YOUR Heart!



Randomized Trial to Prevent Vascular Events in HIV




Meet Our Team	For Participants	Our Sites	Site Resources	My ♥ Matters Blog
---------------	------------------	-----------	----------------	-------------------

The REPRIEVE Follow YOUR Heart Campaign invites you to read the latest *My Heart Matters Blog*, [What YOU need to know about the salt in your diet!](#) This blog post, written by Corinne Rivard, breaks down why salt in your diet is important but also how too much may affect your health.

Participant moving? Transfer REPRIEVE participants to nearby sites!

Given the duration of REPRIEVE, it is likely one or more of your participants may move out of the area. REPRIEVE has sites in nearly every state in the US and in 11 countries around the world! So if one of your REPRIEVE participants is moving, chances are there is another site nearby! [Click here](#) to find a map of our clinical sites.

REPRIEVE follows [SOP ACTG-119, Study Participant Transfer](#) for participant transfers, however specific protocol guidance can be found in section 12.5 of the REPRIEVE (A5332) MOPs.



Specimen Collection Reminder

Specimen collection is very important in both REPRIEVE (A5332) and the Mechanistic Substudy of REPRIEVE (A5333s). The studies rely on the collection of specimens for the validity of the results and to help assess for the safety of pitavastatin use among people with HIV. For those participants who may not have initially consented to specimen collection, we ask that while reconsenting for Version 5.0, sites encourage participants to consent to specimen collection.

For REPRIEVE (A5332) utilize the Lab Processing Chart according to your site designation (ACTG or non-ACTG) located in the Lab Resources folder on the REPRIEVE (A5332) PSWP.

If you would like talking points to help when reconsenting for this purpose please email Emma Kileel (ekileel@mg.harvard.edu), the CCC has developed talking points to help facilitate this conversation!

Save the Date!
Tuesday, September, 17th 2019
1:00 – 2:00 PM ET

For the next Monthly Site Call!

If you missed the July monthly site call, [click here](#) to download slides.



REPRIEVE (A5332): Are you up to date?

For A5332 please use:

Protocol Version 5.0 dated 04/01/2019

MOPS Version 5.0 dated 04/15/2019

A5332 LPC for ACTG Sites Version 5.0 dated 04/11/2019

A5332 LPC for Non-ACTG Sites Version 5.0 dated 04/11/2019

These documents are on the [A5332 PSWP](#)

Mechanistic Substudy of REPRIEVE (A5333s): Are you up to date?

For A5333s please use

Protocol Version 5.0 dated 04/01/2019

MOPS Version 4.0 dated 04/10/2018

A5333s LPC Version 4.0 dated 03/23/2018

These documents are on the [A5333s PSWP](#)

For future reference, all newsletters are available on the [REPRIEVE Website](#).

We welcome ideas and suggestions for future newsletters. Please submit any comments or suggestions to the REPRIEVE News team at reprieve.news@fstrf.org



REPRIEVE Trial Clinical Coordinating Center

Massachusetts General Hospital

55 Fruit Street, 5LON 207

Boston, MA USA 02144

Our mailing address is:

reprieve.news@fstrf.org

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

This email was sent to ekileel@mgh.harvard.edu
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)
Massachusetts General Hospital · 5 Longfellow Place · Boston, MA 02214 · USA

